These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 17473209)

  • 41. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action.
    Park H; Aiyar SE; Fan P; Wang J; Yue W; Okouneva T; Cox C; Jordan MA; Demers L; Cho H; Kim S; Song RX; Santen RJ
    Cancer Res; 2007 Jun; 67(12):5717-26. PubMed ID: 17575138
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene.
    Yue W; Zhou D; Chen S; Brodie A
    Cancer Res; 1994 Oct; 54(19):5092-5. PubMed ID: 7923123
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM
    Expert Rev Anticancer Ther; 2007 May; 7(5):627-34. PubMed ID: 17492927
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
    Lipton A; Leitzel K; Chaudri-Ross HA; Evans DB; Ali SM; Demers L; Hamer P; Brown-Shimer S; Pierce K; Gaur V; Carney W
    J Clin Oncol; 2008 Jun; 26(16):2653-8. PubMed ID: 18443351
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
    Sabnis G; Brodie A
    Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pure antiestrogens as a new therapy for breast cancer.
    England GM; Jordan VC
    Oncol Res; 1997; 9(8):397-402. PubMed ID: 9436192
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
    Bottini A; Generali D; Brizzi MP; Fox SB; Bersiga A; Bonardi S; Allevi G; Aguggini S; Bodini G; Milani M; Dionisio R; Bernardi C; Montruccoli A; Bruzzi P; Harris AL; Dogliotti L; Berruti A
    J Clin Oncol; 2006 Aug; 24(22):3623-8. PubMed ID: 16877730
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
    Jelovac D; Sabnis G; Long BJ; Macedo L; Goloubeva OG; Brodie AM
    Cancer Res; 2005 Jun; 65(12):5380-9. PubMed ID: 15958587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiestrogenic effect of 20S-protopanaxadiol and its synergy with tamoxifen on breast cancer cells.
    Yu Y; Zhou Q; Hang Y; Bu X; Jia W
    Cancer; 2007 Jun; 109(11):2374-82. PubMed ID: 17464948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
    Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment.
    Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura S; Lawrence J; MacMahon LP; Yue W; Berstein L
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):155-65. PubMed ID: 16024245
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
    Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
    Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
    Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
    Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Apigenin inhibits HGF-promoted invasive growth and metastasis involving blocking PI3K/Akt pathway and beta 4 integrin function in MDA-MB-231 breast cancer cells.
    Lee WJ; Chen WK; Wang CJ; Lin WL; Tseng TH
    Toxicol Appl Pharmacol; 2008 Jan; 226(2):178-91. PubMed ID: 17961621
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (mcf-7) in nude mice.
    Chen J; Hui E; Ip T; Thompson LU
    Clin Cancer Res; 2004 Nov; 10(22):7703-11. PubMed ID: 15570004
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aromatase inhibitors in human lung cancer therapy.
    Weinberg OK; Marquez-Garban DC; Fishbein MC; Goodglick L; Garban HJ; Dubinett SM; Pietras RJ
    Cancer Res; 2005 Dec; 65(24):11287-91. PubMed ID: 16357134
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.
    Hodges-Gallagher L; Valentine CD; Bader SE; Kushner PJ
    Breast Cancer Res Treat; 2007 Nov; 105(3):297-309. PubMed ID: 17186358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.